Status:
TERMINATED
Integrated Radiographic and Metabolomics Risk Assessment in Patients With Interstitial Lung Diseases
Lead Sponsor:
Corewell Health East
Conditions:
Lung Diseases, Interstitial
Pulmonary Fibrosis
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to find out if combining a state-of-the-art form imaging modality with metabolomics in different types of Interstitial Lung Diseases (ILD) patients compared to controls wi...
Detailed Description
Interstitial lung diseases (ILD) are a group of chronic, progressive lung disorders. The most common ILD is idiopathic pulmonary fibrosis (IPF) with an average survival ranging between 2.5-5 years aft...
Eligibility Criteria
Inclusion
- Patients greater than 18 years of age
- Patients with a PFT-Pulmonary function test \</=3 month plus seven days
- Patients with idiopathic pulmonary fibrosis (IPF), or
- Patients with interstitial lung disease (ILD) other than IPF, or
- Patients with chronic obstructive pulmonary disease COPD/emphysema based on Principal's Investigator's assessment/review, or
- Control subject, someone without a diagnosis of above and deemed and "healthy control" by the PI.
- COPD/emphysema and control subjects will be age matched +/-10 years to the ILD subjects.
Exclusion
- Patients less than 18 years of age
- Patients with active malignancy in past one year, except for basal and squamous cell skin cancer
- Patients without a PFT-Pulmonary function test \</=3 month plus seven days
- Pregnant females
- Cognitive impairment and unable to follow directions, per PI discretion
Key Trial Info
Start Date :
September 30 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 20 2022
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT04119115
Start Date
September 30 2021
End Date
October 20 2022
Last Update
May 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beaumont Health
Royal Oak, Michigan, United States, 48073